Replimune Group, Inc. $REPL Stock: Nan Fung Trinity HK Ltd. Cuts Position

Nan Fung Trinity HK Ltd. decreased its stake in shares of Replimune Group, Inc. (NASDAQ:REPL) by 46.0% during the 3rd quarter, Holdings Channel.com reports. The firm owned 133,800 shares of the company’s stock after selling 113,965 shares during the period. Nan Fung Trinity HK Ltd.’s holdings in Replimune Group were worth $1,772,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Replimune Group in the 3rd quarter valued at about $64,000. Allworth Financial LP purchased a new stake in shares of Replimune Group during the second quarter worth approximately $62,000. Essential Partners LLC increased its stake in shares of Replimune Group by 562,400.0% during the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after buying an additional 5,624 shares during the period. Legal & General Group Plc purchased a new stake in shares of Replimune Group during the second quarter worth approximately $85,000. Finally, WINTON GROUP Ltd acquired a new stake in Replimune Group in the second quarter valued at approximately $115,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Analyst Upgrades and Downgrades

REPL has been the subject of a number of recent research reports. JPMorgan Chase & Co. lifted their price target on shares of Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 26th. Cantor Fitzgerald reissued an “overweight” rating on shares of Replimune Group in a research report on Monday, October 5th. Wall Street Zen raised shares of Replimune Group from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. Leerink Partners raised their price objective on shares of Replimune Group from $19.00 to $31.00 and gave the company an “outperform” rating in a report on Thursday, October 29th. Finally, Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $14.33.

Replimune Group Stock Up 0.9%

NASDAQ:REPL opened at $21.98 on Friday. The stock has a 50-day simple moving average of $14.63 and a 200-day simple moving average of $9.97. Replimune Group, Inc. has a 1 year low of $1.50 and a 1 year high of $23.54. The company has a quick ratio of 6.90, a current ratio of 7.11 and a debt-to-equity ratio of 0.59.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Wednesday, October 28th. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.24. On average, equities analysts forecast that Replimune Group, Inc. will post -2.40 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Emily Hill sold 9,256 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $14.28, for a total value of $132,175.68. Following the completion of the transaction, the chief financial officer directly owned 215,852 shares of the company’s stock, valued at $3,082,366.56. This represents a 4.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Joseph P. Slattery sold 5,200 shares of the company’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $21.80, for a total value of $113,360.00. Following the completion of the transaction, the director directly owned 1,467 shares of the company’s stock, valued at $31,980.60. This trade represents a 78.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 35,956 shares of company stock worth $654,036 over the last 90 days. 5.40% of the stock is owned by insiders.

Replimune Group Profile

Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.